PortalPublikationenIndividual outcome prediction for myelodysplastic syndrome (...

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

Standard

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. / Heuser, Michael; Gabdoulline, Razif; Löffeld, Patrick; Dobbernack, Vera; Kreimeyer, Henriette; Pankratz, Mira; Flintrop, Madita; Liebich, Alessandro; Klesse, Sabrina; Panagiota, Victoria; Stadler, Michael; Wichmann, Martin; Shahswar, Rabia; Platzbecker, Uwe; Thiede, Christian; Schroeder, Thomas; Kobbe, Guido; Geffers, Robert; Schlegelberger, Brigitte; Göhring, Gudrun; Kreipe, Hans-Heinrich; Germing, Ulrich; Ganser, Arnold; Kröger, Nicolaus; Koenecke, Christian; Thol, Felicitas.

in: ANN HEMATOL, Jahrgang 96, Nr. 8, 08.2017, S. 1361-1372.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Heuser, M, Gabdoulline, R, Löffeld, P, Dobbernack, V, Kreimeyer, H, Pankratz, M, Flintrop, M, Liebich, A, Klesse, S, Panagiota, V, Stadler, M, Wichmann, M, Shahswar, R, Platzbecker, U, Thiede, C, Schroeder, T, Kobbe, G, Geffers, R, Schlegelberger, B, Göhring, G, Kreipe, H-H, Germing, U, Ganser, A, Kröger, N, Koenecke, C & Thol, F 2017, 'Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation', ANN HEMATOL, Jg. 96, Nr. 8, S. 1361-1372. https://doi.org/10.1007/s00277-017-3027-5

APA

Heuser, M., Gabdoulline, R., Löffeld, P., Dobbernack, V., Kreimeyer, H., Pankratz, M., Flintrop, M., Liebich, A., Klesse, S., Panagiota, V., Stadler, M., Wichmann, M., Shahswar, R., Platzbecker, U., Thiede, C., Schroeder, T., Kobbe, G., Geffers, R., Schlegelberger, B., ... Thol, F. (2017). Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. ANN HEMATOL, 96(8), 1361-1372. https://doi.org/10.1007/s00277-017-3027-5

Vancouver

Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M et al. Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. ANN HEMATOL. 2017 Aug;96(8):1361-1372. https://doi.org/10.1007/s00277-017-3027-5

Bibtex

@article{a399fd7cd63c46edb6ac8767c986d8ac,
title = "Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation",
abstract = "We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.",
keywords = "Acute Disease, Adult, Aged, Algorithms, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Male, Middle Aged, Multivariate Analysis, Mutation, Myelodysplastic Syndromes, Neoplasms, Second Primary, Outcome Assessment (Health Care), Precision Medicine, Prognosis, Proportional Hazards Models, Risk Assessment, Risk Factors, Sequence Analysis, DNA, Survival Analysis, Transplantation, Homologous, Young Adult, Journal Article, Multicenter Study",
author = "Michael Heuser and Razif Gabdoulline and Patrick L{\"o}ffeld and Vera Dobbernack and Henriette Kreimeyer and Mira Pankratz and Madita Flintrop and Alessandro Liebich and Sabrina Klesse and Victoria Panagiota and Michael Stadler and Martin Wichmann and Rabia Shahswar and Uwe Platzbecker and Christian Thiede and Thomas Schroeder and Guido Kobbe and Robert Geffers and Brigitte Schlegelberger and Gudrun G{\"o}hring and Hans-Heinrich Kreipe and Ulrich Germing and Arnold Ganser and Nicolaus Kr{\"o}ger and Christian Koenecke and Felicitas Thol",
year = "2017",
month = aug,
doi = "10.1007/s00277-017-3027-5",
language = "English",
volume = "96",
pages = "1361--1372",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "8",

}

RIS

TY - JOUR

T1 - Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation

AU - Heuser, Michael

AU - Gabdoulline, Razif

AU - Löffeld, Patrick

AU - Dobbernack, Vera

AU - Kreimeyer, Henriette

AU - Pankratz, Mira

AU - Flintrop, Madita

AU - Liebich, Alessandro

AU - Klesse, Sabrina

AU - Panagiota, Victoria

AU - Stadler, Michael

AU - Wichmann, Martin

AU - Shahswar, Rabia

AU - Platzbecker, Uwe

AU - Thiede, Christian

AU - Schroeder, Thomas

AU - Kobbe, Guido

AU - Geffers, Robert

AU - Schlegelberger, Brigitte

AU - Göhring, Gudrun

AU - Kreipe, Hans-Heinrich

AU - Germing, Ulrich

AU - Ganser, Arnold

AU - Kröger, Nicolaus

AU - Koenecke, Christian

AU - Thol, Felicitas

PY - 2017/8

Y1 - 2017/8

N2 - We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.

AB - We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.

KW - Acute Disease

KW - Adult

KW - Aged

KW - Algorithms

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Mutation

KW - Myelodysplastic Syndromes

KW - Neoplasms, Second Primary

KW - Outcome Assessment (Health Care)

KW - Precision Medicine

KW - Prognosis

KW - Proportional Hazards Models

KW - Risk Assessment

KW - Risk Factors

KW - Sequence Analysis, DNA

KW - Survival Analysis

KW - Transplantation, Homologous

KW - Young Adult

KW - Journal Article

KW - Multicenter Study

U2 - 10.1007/s00277-017-3027-5

DO - 10.1007/s00277-017-3027-5

M3 - SCORING: Journal article

C2 - 28612220

VL - 96

SP - 1361

EP - 1372

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 8

ER -